RPS6KB1 and lung adenocarcinoma: These findings demonstrate that elevated P70S6K activity can specifically mediate resistance to platinum-based chemotherapy in lung adenocarcinoma, which can be effectively targeted with the dual PI3K/mTOR inhibitor dactolisib.